Premium
Association of differentiated thyroid carcinoma with HLA‐DR7
Author(s) -
Sridama Vitaya,
Hara Yoshihito,
Fauchet Rene,
Degroot Leslie J.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850901)56:5<1086::aid-cncr2820560521>3.0.co;2-9
Subject(s) - medicine , thyroid cancer , thyroid , thyroid carcinoma , follicular phase , gastroenterology , human leukocyte antigen , cancer , carcinoma , follicular carcinoma , oncology , pathology , immunology , papillary carcinoma , antigen
Seventy‐four American white thyroid cancer patients were typed for HLA‐A, B, and DR antigens. A significant increase in HLA‐DR7 was found in the nonradiation‐associated thyroid cancer patients (42.5%, 20/47 cases), compared to 22.8% of 979 normal controls. The association is stronger in the follicular and mixed papillary—follicular subgroup (52.0%, 13/25 cases, P corrected <0.01). The occurrence of various malignancies in family members was found in 57.9% of HLA‐DR7 positive patients, versus 20% of HLA‐DR7 negative patients, in a retrospective record review. Although the frequency of HLA‐DR7 was not increased in the radiation‐associated thyroid cancer patients (22.2%, 6/27 cases), the interval from the irradiation date to the onset date of thyroid cancer was shorter in HLA‐DR7 positive cases (17.3 ± 6.2 years) than in HLA‐DR7 negative patients (29.4 ± 11.5 years). This data suggest that HLA‐DR7 is associated with and may influence development of thyroid cancer.